Tocagen Inc

Tocagen — Forte Biosciences — Investor Presentation (August 2023)

34 slides from Tocagen's investor presentation, Aug 1, 2023

  1. Slide 1: Forte Biosciences Corporate Overview

    Exhibit 99.2 FORTE BIOSCIENCES CORPORATE OVERVIEW CORPORATE PRESENTATION AUGUST 1, 2023

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ¡ Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securitie

  3. Slide 3: Experienced Management

    EXPERIENCED MANAGEMENT Forte’s management has extensive experience in manufacturing, quality, regulatory and clinical development Paul Wagner, Ph.D., CFA – CEO Hubert Chen, M.D. – Chief Scientific Officer Tony Riley – Chief Financial Officer Chris Roenfeldt, PMP – Chief Operating Officer Steven Ruhl

  4. Slide 4: FB-102 Program Overview

    FB-102 PROGRAM OVERVIEW

  5. Slide 5: FB-102 Overview

    FB-102 OVERVIEW + • CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK, CD 8 T cells and Tregs + • FB-102 (Forte’s anti-CD122 antibody) is designed to mediate NK and CD 8 T cells specifically • Significant amount of PoC preclinical data supports activity of CD-122 blockade, in

  6. Slide 6: Anti-CD122: Highlights of Preclinical Data

    ANTI-CD122: HIGHLIGHTS OF PRECLINICAL DATA

  7. Slide 7: Anti-CD122 Blockade Has Demonstrated Efficacy in Multiple Animal Models

    ANTI-CD122 BLOCKADE HAS DEMONSTRATED EFFICACY IN MULTIPLE ANIMAL MODELS Disease Species Outcome Reference GVHD Mouse Prolonged survival JN Bio patent, 2015 Vitiligo Mouse Enhanced repigmentation Sci Transl Med, 2018 Alopecia areata Mouse Prevented fur loss Nature Med, 2014 Type 1 diabetes Mouse Dela

  8. Slide 8: Anti-CD122 in a Humanized Mouse Model of Acute GVHD

    ANTI-CD122 IN A HUMANIZED MOUSE MODEL OF ACUTE GVHD: AMELIORATED BODY WEIGHT LOSS AND PROLONGED SURVIVAL Humanized mouse model of graft vs host disease Aggressive, rapid onset of GVHD: significant weight loss and mortality within 2 weeks Immunodeficient Transfer of peripheral (NOG) mice blood mononu

  9. Slide 9: CD-122 Blockade Produces Significant Repigmentation in Mouse Vitiligo Model

    CD-122 BLOCKADE PRODUCES SIGNIFICANT REPIGMENTATION IN A MOUSE VITILIGO MODEL Richmond et al. Sci Transl Med. 2018 July 18; 10(450) Following 8 weeks of anti-CD122 treatment (weeks 12-20), the vitiligo mice demonstrated a statistically significant change in tail pigmentation (p=0.0001)

  10. Slide 10: Anti-CD122 in Mouse Model of Vitiligo: Durable Response with Infrequent Dosing

    ANTI-CD122 IN A MOUSE MODEL OF VITILIGO: POTENTIAL OF DURABLE RESPONSE WITH INFREQUENT DOSING REGIMEN Note: anti-mouse CD122 (surrogate molecule) was used in these studies. 10

  11. Slide 11: Anti-CD122 as Prophylaxis Against Fur Loss in Alopecia Areata Mouse Model

    ANTI-CD122 AS AN EFFECTIVE PROPHYLAXIS AGAINST FUR LOSS IN A MOUSE MODEL OF ALOPECIA AREATA Anti-CD122 C3H/HeJ mice were treated systemically from the time of grafting with anti-CD122. Xing et al. Nature Medicine Vol 20, No. 9, p 1043 Note: anti-mouse CD122 (surrogate molecule) was used in these stu

  12. Slide 12: FB-102 Development Strategy: Prioritization of Indications

    FB-102 DEVELOPMENT STRATEGY: PRIORITIZATION OF INDICATIONS

  13. Slide 13: Potential Indications of Anti-CD122: GVHD and Vitiligo as First-Tier Choices

    POTENTIAL INDICATIONS OF ANTI-CD122: GRAFT-VS-HOST DISEASE (GVHD) AND VITILIGO AS FIRST-TIER CHOICES Strength of existing data & Timeline/resource to Commercial opportunity w/ Overall score Indication mechanism of action proof-of-concept in patients projected target product profile (product of 3 sub

  14. Slide 14: Graft vs Host Disease: A Serious Complication of Allogeneic Stem Cell Transplantation

    GRAFT VS HOST DISEASE (GVHD): A SERIOUS COMPLICATION OF ALLOGENEIC STEM CELL TRANSPLANTATION Cause: donor immune cells attack host tissues Classification Acute (~5K US prevalence - NIH) - Occurs in up to 50% of recipients. - Onset typically within 3 months of transplant - Usually combination or orga

  15. Slide 15: CD8 and NK Cells in Pathogenesis of Acute GVHD

    CD8 AND NK CELLS IN THE PATHOGENESIS OF ACUTE GVHD: POTENTIAL OF ANTI-CD122 ANTAGONISM WITH FB102 Anti-CD122: blocking key cellular mediators of GVHD IFNg IL-2 Inflammation & apoptosis Devetten MP, Biol Blood Marrow Transplant. 2004;10:815. Simonetta F, Front Immunol. 2017;8:465. Khandelwal P, Biol

  16. Slide 16: Large Unmet Need in Vitiligo and Alopecia Areata

    LARGE UNMET NEED IN VITILIGO AND ALOPECIA AREATA (COMBINED $6 BILLION MARKET BY 2026) Vitiligo Vitiligo is an autoimmune disease of the skin mediated primarily by NK and CD8+ T cells that kill melanocytes and create white spots. In the US there are approximately 2 m people with vitiligo. The global

  17. Slide 17: FB-102 in Graft vs Host Disease

    FB-102 IN GRAFT VS HOST DISEASE

  18. Slide 18: Acute GVHD: Treatment Paradigm and Development Pipeline

    ACUTE GVHD: TREATMENT PARADIGM AND DEVELOPMENT PIPELINE https://www.lls.org/booklet/graft-versus-host-disease https://www.jakafi.com/pdf/prescribing-information.pdf 18

  19. Slide 19: Potential Indications and Clinical Success Criteria in Acute GVHD

    POTENTIAL INDICATIONS AND CLINICAL SUCCESS CRITERIA OF ANTI-CD122 IN ACUTE GVHD Corticosteroids First-line Goal: improve Day 28 ORR vs. Anti- Second-line CD122 ruxolitinib monotherapy Anti- Goal: achieve Day 28 ORR >60% Third-line CD122 after ruxolitinib failure https://www.lls.org/booklet/graft-ver

  20. Slide 20: Approval of Ruxolitinib in Acute GVHD Based on Open-Label Single-Arm Study

    APPROVAL OF RUXOLITINIB IN ACUTE GVHD WAS BASED ON THE RESULTS FROM AN OPEN-LABEL, SINGLE-ARM STUDY Efficacy is based on Day 28 overall response rate as defined by CIBMTR criteria. https://www.jakafi.com/pdf/prescribing-information.pdf 20

  21. Slide 21: Chronic GVHD: Treatment Paradigm and Development Pipeline

    CHRONIC GVHD: TREATMENT PARADIGM AND DEVELOPMENT PIPELINE https://www.lls.org/booklet/graft-versus-host-disease https://www.rxabbvie.com/pdf/imbruvica_pi.pdf https://www.jakafi.com/pdf/prescribing-information.pdf https://products.sanofi.us/rezurock/rezurock.pdf 21

  22. Slide 22: Potential Indications and Clinical Success Criteria in Chronic GVHD

    POTENTIAL INDICATIONS AND CLINICAL SUCCESS CRITERIA OF ANTI-CD122 IN CHRONIC GVHD Corticosteroids First-line Second-line Goal: improve Month 6 ORR Anti- (esp. CR) vs. standard of care. CD122 Third-line Anti- Fourth-line https://www.lls.org/booklet/graft-versus-host-disease Goal: achieve Month 6 ORR

  23. Slide 23: Approval of Rezurock in Chronic GVHD Based on Open-Label Single-Arm Study

    APPROVAL OF REZUROCK IN CHRONIC GVHD WAS BASED ON THE RESULTS FROM AN OPEN-LABEL, SINGLE-ARM STUDY Efficacy is based on overall response rate after 6 months of treatment as defined by the 2014 NIH response criteria. https://products.sanofi.us/rezurock/rezurock.pdf 23

  24. Slide 24: Kadmon Purchased by Sanofi for $1.9B

    KADMON PURCHASED BY SANOFI FOR $1.9B TO FURTHER STRENGTHEN GROWTH OF TRANSPLANT BUSINESS 24

  25. Slide 25: FB-102 Graft vs Host Disease Preclinical Data

    FB-102 GRAFT VS HOST DISEASE PRECLINICAL DATA

  26. Slide 26: Chronic GVHD Study with Anti-CD122 and Ruxolitinib

    CHRONIC GVHD STUDY WITH ANTI-CD122 AND RUXOLITINIB End of Treatment start study 40 50 60 Day 1 10 20 30 Vehicle FB650 (100 mpk IP every other day) Ruxolitinib (60 mpk PO twice daily) N=16-18 per group 26

  27. Slide 27: Chronic GVHD Study Results: GVHD Score

    CHRONIC GVHD STUDY RESULTS: GVHD SCORE Treatment start 3 Vehicle Vehicle 2 Anti-CD122 Ruxolitinib Ruxolitinib 1 0 Anti-CD122 30 34 38 42 46 50 54 58 62 66 Days after transplant Mean (SEM), n=16-18 per group Day 60 results: P<0.01 for Vehicle vs Anti-CD122, P<0.05 for Ruxolitinib vs Anti-CD122 27 GVH

  28. Slide 28: Generating Preclinical Efficacy Data in Humanized Mouse Model of Acute GVHD

    GENERATING PRECLINICAL EFFICACY DATA IN A HUMANIZED MOUSE MODEL OF ACUTE GVHD Humanized mouse model of graft vs host disease 28

  29. Slide 29: Dose-Ranging Investigation of FB102 in Humanized Mouse Model: Therapeutic Mode

    DOSE-RANGING INVESTIGATION OF FB102 IN A HUMANIZED MOUSE MODEL OF ACUTE GVHD: THERAPEUTIC MODE Irradiation & End of PBMC transplantation treatment 1 2 3 4 5 6 8 10 12 13 14 Day 7 9 11 FB102 Once-daily IP administration Start dosing on Day 5, (75, 125, 175 mpk) once daily Vehicle Once-daily IP admini

  30. Slide 30: FB102 Survival Benefits: Therapeutic Mode

    FB102 SURVIVAL BENEFITS: THERAPEUTIC MODE Start of daily treatment 1 1 1 1 10 0 0 0 00 0 0 0 0% % % % % FB102(75): 90% FB102(175): 90% 8 8 8 8 80 0 0 0 0% % % % % FB102(125): 80% 6 6 6 6 60 0 0 0 0% % % % % Ruxolitinib: 60% 4 4 4 4 40 0 0 0 0% % % % % 2 2 2 2 20 0 0 0 0% % % % % Vehicle: 0% 0 0 0 0

  31. Slide 31: Mono vs Combination Therapies with FB102, Ruxolitinib or Corticosteroids

    MONO VS COMBINATION THERAPIES WITH FB102, RUXOLITINIB OR CORTICOSTEROIDS Irradiation & End of study PBMC injection (D18) Day 1 5 8 12 15 18 Ruxolitinib Twice-daily oral (60 mpk) FB102+Ruxolitinib Once-daily IP + twice-daily oral (75 mpk+60 mpk) Placebo Once-daily IP + twice-daily oral (Combination o

  32. Slide 32: FB102 Survival Benefits: Combination with Ruxolitinib vs Monotherapy

    FB102 SURVIVAL BENEFITS: COMBINATION WITH RUXOLITINIB VS MONOTHERAPY Start of daily treatment 100% 1 10 00 0% % FB102+Rux: 90% 8 8 80 0 0% % % 6 6 60 0 0% % % 4 4 40 0 0% % % Ruxolitinib: 30% 2 2 20 0 0% % % Vehicle: 0% 0 0 0% % % 1 1 1 3 3 3 5 5 5 7 7 7 9 9 9 1 1 11 1 1 1 1 13 3 3 1 1 15 5 5 1 1 17

  33. Slide 33: Translation of Humanized Acute GVHD Mouse Findings into Patient Response

    TRANSLATION OF HUMANIZED ACUTE GVHD MOUSE FINDINGS INTO PATIENT RESPONSE: PROMISING FB102 RESULTS Magnitude of FB102 preclinical efficacy correlates with positive clinical response. Preclinical Data Indication/ Clinical Data Company Candidate Mechanism (survival in humanized Phase (Day 28 ORR) GVHD

  34. Slide 34: FB-102 Overview

    FB-102 OVERVIEW + • CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK, CD 8 T cells and Tregs + • FB-102 (Forte’s anti-CD122 antibody) is designed to mediate NK and CD 8 T cells specifically • Significant amount of PoC preclinical data supports activity of CD-122 blockade, in

Forte Biosciences — Investor Presentation (August 2023) on 6ix